165 related articles for article (PubMed ID: 37851459)
1. Janus Kinase Inhibitors and Adverse Events of Acne: A Systematic Review and Meta-Analysis.
Martinez J; Manjaly C; Manjaly P; Ly S; Zhou G; Barbieri J; Mostaghimi A
JAMA Dermatol; 2023 Dec; 159(12):1339-1345. PubMed ID: 37851459
[TBL] [Abstract][Full Text] [Related]
2. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.
Sun C; Su Z; Zeng YP
Inflamm Res; 2023 Sep; 72(9):1861-1871. PubMed ID: 37707560
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis.
Chen TL; Lee LL; Huang HK; Chen LY; Loh CH; Chi CC
JAMA Dermatol; 2022 Nov; 158(11):1254-1261. PubMed ID: 36001310
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis.
Ingrassia JP; Maqsood MH; Gelfand JM; Weber BN; Bangalore S; Lo Sicco KI; Garshick MS
JAMA Dermatol; 2024 Jan; 160(1):28-36. PubMed ID: 37910098
[TBL] [Abstract][Full Text] [Related]
6. Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.
Liu M; Gao Y; Yuan Y; Yang K; Shen C; Wang J; Tian J
JAMA Netw Open; 2023 Jun; 6(6):e2320351. PubMed ID: 37368402
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase inhibitors for the treatment of COVID-19.
Kramer A; Prinz C; Fichtner F; Fischer AL; Thieme V; Grundeis F; Spagl M; Seeber C; Piechotta V; Metzendorf MI; Golinski M; Moerer O; Stephani C; Mikolajewska A; Kluge S; Stegemann M; Laudi S; Skoetz N
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015209. PubMed ID: 35695334
[TBL] [Abstract][Full Text] [Related]
8. The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.
Yoon S; Kim K; Shin K; Kim HS; Kim B; Kim MB; Ko HC; Kim YH
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):52-61. PubMed ID: 37597261
[TBL] [Abstract][Full Text] [Related]
9. Topical benzoyl peroxide for acne.
Yang Z; Zhang Y; Lazic Mosler E; Hu J; Li H; Zhang Y; Liu J; Zhang Q
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD011154. PubMed ID: 32175593
[TBL] [Abstract][Full Text] [Related]
10. Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials.
Ireland PA; Jansson N; Spencer SKR; Braden J; Sebaratnam D
JAMA Dermatol; 2024 Mar; 160(3):281-289. PubMed ID: 38294793
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Li C; Sun X; Zhao K; Meng F; Li L; Mu Z; Han X
Dermatology; 2022; 238(4):725-735. PubMed ID: 34455413
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
Zhang L; Guo L; Wang L; Jiang X
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1937-1946. PubMed ID: 35608188
[TBL] [Abstract][Full Text] [Related]
13. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
14. Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.
Papierzewska M; Waśkiel-Burnat A; Rudnicka L
Clin Drug Investig; 2023 May; 43(5):325-334. PubMed ID: 37138134
[TBL] [Abstract][Full Text] [Related]
15. Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials.
Wollenberg A; Kircik L; Simpson E; Brinker D; Katoh N; Rueda MJ; Issa M; Yang F; Feely M; Alexis A
Dermatitis; 2023; 34(4):308-314. PubMed ID: 36749121
[No Abstract] [Full Text] [Related]
16. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
Wan H; Jia H; Xia T; Zhang D
Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
[TBL] [Abstract][Full Text] [Related]
17. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring.
Samuel C; Cornman H; Kambala A; Kwatra SG
Dermatol Ther (Heidelb); 2023 Mar; 13(3):729-749. PubMed ID: 36790724
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
Chen CY; Chen WC; Hsu CK; Chao CM; Lai CC
Int Immunopharmacol; 2021 Oct; 99():108027. PubMed ID: 34343937
[TBL] [Abstract][Full Text] [Related]
19. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis.
Wei Q; Wang H; Zhao J; Luo Z; Wang C; Zhu C; Su N; Zhang S
Front Pharmacol; 2023; 14():1237234. PubMed ID: 37614310
[No Abstract] [Full Text] [Related]
[Next] [New Search]
